Fermenta Biotech Ltd

₹ 184 -0.11%
05 Dec - close price
About

FBL, incorporated in 1986, has two business segments; i.e. manufacturing of active pharmaceutical ingredients (APIs) and lease rental business for commercial properties developed in Thane.

Key Points

Key Product Segments
The company’s business can be classified majorly under five segments which are Vitamin D3, specialty APIs, biological enzymes and biotech based environmental solutions and rental business. FBL manufactures a range of Vitamin D3 variants having an optimal mix between human and animal feed products. [1]

  • Market Cap 543 Cr.
  • Current Price 184
  • High / Low 320 / 174
  • Stock P/E 38.6
  • Book Value 134
  • Dividend Yield 0.68 %
  • ROCE 9.78 %
  • ROE 7.90 %
  • Face Value 5.00

Pros

Cons

  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last 3 years: -3.57%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
80.78 66.45 72.10 100.93 93.32 87.67 90.90 108.88 99.01 85.41 94.66 84.46 90.12
65.17 52.51 58.58 76.08 65.68 64.52 72.84 81.30 81.47 73.14 76.11 76.43 78.86
Operating Profit 15.61 13.94 13.52 24.85 27.64 23.15 18.06 27.58 17.54 12.27 18.55 8.03 11.26
OPM % 19.32% 20.98% 18.75% 24.62% 29.62% 26.41% 19.87% 25.33% 17.72% 14.37% 19.60% 9.51% 12.49%
5.20 3.44 2.65 1.28 0.94 0.66 3.74 1.07 2.35 1.13 2.97 3.90 2.59
Interest 4.91 5.39 4.04 3.62 5.47 3.96 5.02 4.18 4.44 4.12 4.48 4.52 4.90
Depreciation 3.73 3.80 3.93 3.88 4.54 4.67 5.94 5.46 5.97 6.21 6.03 6.20 6.26
Profit before tax 12.17 8.19 8.20 18.63 18.57 15.18 10.84 19.01 9.48 3.07 11.01 1.21 2.69
Tax % -168.28% -18.93% 12.07% 12.51% 19.55% 27.21% 10.79% 32.72% 30.70% 40.72% 17.71% 13.22% 20.82%
Net Profit 32.66 9.75 7.21 16.31 14.94 11.05 9.67 12.79 6.57 1.82 9.07 1.05 2.13
EPS in Rs 11.88 3.32 2.45 5.54 5.08 3.75 3.29 4.35 2.23 0.62 3.08 0.36 0.72
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
15 18 18 15 14 6 6 13 403 299 371 387 355
10 7 9 11 11 12 14 22 255 229 276 310 305
Operating Profit 5 11 9 4 3 -6 -8 -9 148 70 95 77 50
OPM % 35% 60% 50% 28% 21% -99% -154% -75% 37% 24% 26% 20% 14%
23 9 0 0 0 1 0 0 6 12 6 8 11
Interest 0 0 0 0 0 2 6 11 21 20 19 18 18
Depreciation 1 2 2 2 2 2 3 4 12 15 19 24 25
Profit before tax 27 18 7 2 1 -9 -18 -23 121 48 63 43 18
Tax % 20% 20% 20% 31% 30% 1% -2% -3% 9% -34% 18% 29%
Net Profit 22 15 5 1 1 -9 -18 -24 110 64 52 30 14
EPS in Rs 7.89 5.32 1.93 0.51 0.26 -3.31 -6.63 -8.75 40.13 21.63 17.66 10.27 4.78
Dividend Payout % 26% 47% 96% 161% 157% -6% -3% -2% 1% 23% 14% 12%
Compounded Sales Growth
10 Years: 36%
5 Years: 134%
3 Years: -1%
TTM: -8%
Compounded Profit Growth
10 Years: 15%
5 Years: 30%
3 Years: -36%
TTM: -65%
Stock Price CAGR
10 Years: 14%
5 Years: 6%
3 Years: -3%
1 Year: -36%
Return on Equity
10 Years: 13%
5 Years: 19%
3 Years: 14%
Last Year: 8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
2 2 2 2 2 2 2 2 5 14 14 14 14
Reserves 86 93 92 91 90 80 87 62 245 298 356 382 380
2 6 1 25 35 52 44 143 209 226 234 241 256
9 9 13 13 15 15 12 15 93 71 78 76 87
Total Liabilities 99 110 107 131 143 149 146 223 551 610 683 713 738
13 12 10 8 7 93 94 96 177 197 250 287 282
CWIP 0 5 13 34 63 1 1 0 22 71 57 35 37
Investments 59 36 32 39 40 41 40 118 8 1 13 13 24
27 57 53 51 33 15 12 9 344 341 363 378 394
Total Assets 99 110 107 131 143 149 146 223 551 610 683 713 738

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
-3 31 11 2 -0 -5 -9 1 91 30 63 50
12 -25 -2 -20 -11 -8 20 -89 -97 -39 -44 -32
-8 -7 -8 21 9 14 -13 88 12 -48 -1 -22
Net Cash Flow 1 -0 1 2 -2 1 -2 1 6 -57 18 -4

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 31 5 12 9 5 2 26 8 59 94 95 111
Inventory Days 347 501 392 328
Days Payable 172 208 135 115
Cash Conversion Cycle 31 5 12 9 5 2 26 8 234 387 352 324
Working Capital Days 95 -29 -14 -212 -923 -2,380 -538 -289 97 207 191 208
ROCE % 12% 10% 7% 2% 1% -5% -9% -7% 45% 13% 14% 10%

Shareholding Pattern

Numbers in percentages

Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
59.44 59.44 59.44 59.44 59.44 59.44 59.44 59.44 59.58 59.58 59.58 59.58
0.52 0.52 0.41 0.17 0.25 0.13 0.03 0.01 0.01 0.01 0.01 0.01
0.00 0.00 0.00 0.00 0.24 0.24 0.00 0.00 0.05 0.05 0.05 0.05
38.06 38.06 38.17 38.40 38.09 38.21 38.55 38.57 38.37 38.37 38.37 38.38
1.98 1.98 1.98 1.98 1.98 1.98 1.98 1.98 1.98 1.98 1.98 1.98

* The XBRL reporting format changed from Sep'2022 onwards. The new format added details about banks and foreign portfolio investors. These were not available earlier.
The sudden increase in FII or DII might be because of these changes.

Please click on the line-items to see the names of individual entities.

Documents

Concalls